Agilent Technologies
A
$159.00
+1.73%
Agilent Technologies Inc. is a global leader in life sciences, diagnostics, and applied chemical analysis, providing measurement instruments, consumables, and services to customers in biopharmaceutical, chemical, and clinical laboratories. Spun out of Hewlett-Packard in 1999, the company has established a strong competitive position through its three operating segments: Life Sciences and Applied Markets, Agilent CrossLab, and Applied Markets, with a diverse geographic footprint led by the US and China. The current investor narrative centers on the company's robust operational momentum, highlighted by a recent quarterly earnings beat and raised full-year profit forecast, alongside strategic acquisitions like Biocare Medical to expand in high-margin pathology. However, the stock's recent surge also raises questions about valuation sustainability and the pace of growth in the face of broader market volatility.…
A
Agilent Technologies
$159.00
Related headlines
Investment Opinion: Should I buy A Today?
Rating: Hold. Agilent is a high-quality growth company, but the current price of $159 leaves little upside to the average analyst target of $160.11. The consensus 'Buy' rating (mean 1.67) is tempered by the limited price appreciation potential.
Sign up to view all
A 12-Month Price Forecast
Agilent's fundamentals are strong, with accelerating growth and expanding margins, but the stock's valuation leaves little room for error. The neutral stance reflects the balance between positive operational momentum and limited upside potential. To upgrade to bullish, we would need to see revenue growth exceed 12% and/or a pullback to below $140. A downgrade to bearish would be warranted if growth decelerates below 7% or if margins contract significantly.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Agilent Technologies's 12-month outlook, with a consensus price target around $160.89 and implied upside of +1.2% versus the current price.
Average Target
$160.89
0 analysts
Implied Upside
+1.2%
vs. current price
Analyst Count
—
covering this stock
Price Range
$148 - $185
Analyst target range
Agilent is covered by 19 analysts, with a consensus recommendation of 'Buy' and a mean rating of 1.67 (where 1 is Strong Buy and 5 is Sell). The average price target is $160.11, implying a modest 0.7% upside from the current price of $159. The target range spans from $135 to $185, with the low target suggesting a 15% downside and the high target a 16% upside. The wide spread indicates uncertainty about the sustainability of growth and valuation. Recent ratings actions have been predominantly positive, with upgrades from B of A Securities and Piper Sandler, though Piper Sandler downgraded to Neutral in June. Overall, the consensus is bullish but cautious, reflecting the stock's strong run-up.
Bulls vs Bears: A Investment Factors
Agilent presents a compelling growth story with accelerating revenue, expanding margins, and a strategic pivot toward high-margin diagnostics. However, the stock's valuation has run ahead of fundamentals, with a trailing PE of 31.9x versus the industry's 22x, and analyst targets imply minimal upside. The bull case rests on continued operational outperformance and successful integration of Biocare, while the bear case hinges on valuation compression and macro headwinds. Currently, the evidence slightly favors the bulls given the strong earnings momentum, but the risk-reward is balanced. The key tension is whether Agilent can sustain double-digit growth to justify its premium multiple, or if a slowdown will trigger a de-rating.
Bullish
- Accelerating Revenue Growth: Q2 FY2026 revenue grew 10.0% YoY to $1.835B, up from 7.7% growth in Q1, indicating accelerating demand across life sciences and applied markets. This momentum is driven by strong biopharma spending and recovery in China.
- Expanding Profit Margins: Gross margin expanded to 54.99% in Q2 from 52.61% in Q1, while operating margin reached 21.7%, up from 19.6%. Net income surged 57.7% YoY to $339M, reflecting operational leverage and cost discipline.
- Raised Full-Year Guidance: Following the Q2 beat, management raised the full-year profit forecast, signaling confidence in sustained growth. This positive revision has driven the stock to near its 52-week high of $160.47.
- Strategic Acquisition in Pathology: The Biocare Medical acquisition expands Agilent's high-margin pathology portfolio, a growing niche in diagnostics. This move aligns with the company's strategy to shift toward higher-growth, higher-margin segments.
Bearish
- Elevated Valuation Premium: Trailing PE of 31.9x is 45% above the industry average of 22x, and the PEG ratio of 9.4x suggests the stock is expensive relative to its growth rate. This leaves limited margin for error if growth disappoints.
- Limited Analyst Upside: The average analyst price target of $160.11 implies only 0.7% upside from the current price of $159. With the stock near the high end of its range, the risk-reward is skewed to the downside.
- High Beta and Market Sensitivity: With a beta of 1.229, the stock is more volatile than the market, amplifying downside risk in a downturn. The recent 1-month gain of 19.1% could reverse quickly if sentiment shifts.
- Potential Integration Risks: The Biocare acquisition, while strategic, carries execution risk. Integration challenges could distract management and fail to deliver the expected synergies, impacting margins.
A Technical Analysis
Agilent's stock is in a clear uptrend, with a 1-year price change of +35.7% and currently trading at $159, which is 99.1% of its 52-week range (low $108.35, high $160.47). This positioning near the highs indicates strong momentum and investor confidence, though it also suggests the stock may be overextended in the short term. The stock has outperformed the S&P 500 significantly, with relative strength of 15.2% over the past year, reflecting its strong fundamental performance and sector tailwinds.
Beta
1.23
1.23x market volatility
Max Drawdown
-29.9%
Largest decline past year
52-Week Range
$108-$161
Price range past year
Annual Return
+35.7%
Cumulative gain past year
| Period | A Return | S&P 500 |
|---|---|---|
| 1m | +19.1% | +3.6% |
| 3m | +38.3% | +2.7% |
| 6m | +29.4% | +11.4% |
| 1y | +35.7% | +18.7% |
| ytd | +15.3% | +12.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
A Fundamental Analysis
Agilent's revenue growth is accelerating, with Q2 FY2026 revenue of $1.835 billion, up 10.0% year-over-year, compared to 7.7% growth in the prior quarter. The company's gross margin expanded to 54.99% in Q2, up from 52.61% in Q1, driven by favorable product mix and cost controls. Net income for Q2 was $339 million, a 57.7% increase from the prior year's $215 million, with net margin improving to 18.5% from 12.9%.
Quarterly Revenue
$1.8B
2026-04
Revenue YoY Growth
+10.0%
YoY Comparison
Gross Margin
55.0%
Latest Quarter
Free Cash Flow
$1.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is A Overvalued?
Given Agilent's positive net income, the PE ratio is the primary valuation metric. The trailing PE is 31.9x, while the forward PE is 24.1x, implying the market expects significant earnings growth. The PEG ratio of 9.4x suggests the stock is expensive relative to its growth rate, but this is partly due to the cyclical recovery in earnings. Compared to the industry average PE of 22x, Agilent trades at a 45% premium, reflecting its superior growth and profitability. Historically, the stock's PE has ranged from 15.9x to 80.1x over the past few years, and the current 31.9x is below the mid-range, suggesting room for further multiple expansion if growth continues.
PE
31.9x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 16x~44x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
23.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks: Agilent's debt-to-equity ratio of 0.50 is moderate, but its interest expense of $25M per quarter is manageable given operating income of $399M. The company's free cash flow of $1.256B TTM provides a cushion, yet the payout ratio of 21.6% and dividend yield of 0.68% indicate limited income support. Revenue concentration in the biopharma and applied markets, which account for over half of sales, exposes the company to cyclical R&D budgets. The recent surge in net income (up 57.7% YoY) may not be sustainable if cost controls ease or product mix normalizes.
FAQ
The key risks include: 1) Valuation risk - the stock trades at a 45% premium to the industry, leaving room for de-rating if growth slows. 2) Operational risk - reliance on biopharma R&D budgets, which are cyclical and could be cut in a downturn. 3) Integration risk - the Biocare acquisition may not deliver expected synergies. 4) Macro risk - with a beta of 1.229, the stock is sensitive to market volatility and interest rate changes. The most severe risk is a combination of these factors, which could drive the stock down to its 52-week low of $108.35, a -31.9% loss.
Based on analyst targets and our scenario analysis, the 12-month forecast for Agilent is as follows: Bull case (30% probability) targets $170-$185, base case (50% probability) targets $150-$165, and bear case (20% probability) targets $120-$135. The base case assumes continued mid-to-high single-digit growth and stable margins, aligning with the average analyst target of $160.11. The most likely scenario is the base case, given the company's strong fundamentals but limited upside potential at current prices.
Agilent is overvalued relative to its industry peers, with a trailing PE of 31.9x versus the industry average of 22x, a 45% premium. The PEG ratio of 9.4x further indicates that the stock is expensive relative to its growth rate. Historically, the stock's PE has ranged from 15.9x to 80.1x, and the current 31.9x is below the mid-range, suggesting it is not at extreme levels. The market is pricing in continued double-digit earnings growth, which is achievable given the current momentum, but any disappointment could lead to multiple compression.
Agilent is a high-quality company with accelerating revenue growth (10% YoY) and expanding margins, but the stock is trading near its 52-week high with limited upside to the average analyst target of $160.11 (0.7% upside). The trailing PE of 31.9x is 45% above the industry average, suggesting the market has high expectations. For long-term investors, it could be a good buy on any pullback below $140, but at current levels, the risk-reward is balanced. Short-term traders may find better opportunities elsewhere given the stock's recent run-up.
Agilent is better suited for long-term investment, given its growth trajectory and strategic positioning in life sciences. The company's revenue growth is accelerating, and its expansion into high-margin diagnostics provides a durable competitive advantage. However, with a beta of 1.229 and a recent 1-month gain of 19.1%, the stock is volatile and may experience short-term pullbacks. For long-term investors, a minimum holding period of 3-5 years is recommended to ride out market cycles and benefit from earnings growth. Short-term traders could profit from momentum, but they face higher risk of mean reversion.